AI-generated from publicly available materials.The Insight Series highlights the transformative role of AI in healthcare, featuring insights from Kelly Huang, CEO of Elucid, a company focused on enhancing cardiovascular diagnostics through innovative technology.
Elucid leverages AI to analyze existing imaging data, such as coronary CT angiograms, providing physicians with critical insights into atherosclerosis that were previously unattainable. Their Plaque-IQ software quantifies plaque characteristics in coronary and carotid vessels, while the BioIntegrated FFR-CT integrates anatomical and biological data to assess patient risk for heart attacks and strokes. This approach allows for personalized treatment strategies that are informed by a deeper understanding of each patient's unique disease profile, rather than relying solely on traditional metrics like stenosis or total plaque volume.
Huang emphasizes the importance of transparency in AI applications, arguing that when AI functions as a "black box," it fails to enhance clinical decision-making. Instead, Elucid's platform is designed to support physicians by providing clear, actionable insights derived from comprehensive analyses, thereby bridging the gap between clinical needs and care delivery capabilities.
Looking ahead, Huang advocates for a shift from merely increasing efficiency to fundamentally improving patient outcomes. While many digital health tools have streamlined workflows, they often do not address the underlying quality of clinical decisions. AI should not just expedite processes but also uncover new, actionable information that can lead to better patient care, ultimately reducing cardiovascular events and enhancing overall health outcomes.